Recent earnings reports in the generic drug industry highlight a mixed but resilient operating environment. Sales from several manufacturers have been impacted by declining contributions from older high-value products and ongoing price erosion. Despite these challenges, demand remains robust in many markets, fueled by new product launches and increased volume. Industry experts anticipate that future performance will hinge on effective execution, including restoring supply disruptions and maintaining a steady rollout of new products.
Notable companies performing well in this evolving landscape include Amphastar Pharmaceuticals, Sandoz, and Viatris. In the first half of 2026, Sandoz reported net sales of $5.76 billion, a 5% year-over-year increase, driven largely by its biosimilars business. During the same period, Viatris secured 70 generic approvals and is focused on higher-value complex generics. Amphastar, on the other hand, aims for mid- to high-single-digit sales growth despite facing remediation costs due to an FDA warning letter affecting one of its subsidiaries.
The Zacks Medical – Generic Drugs industry currently ranks #160 out of 247 industries, placing it in the bottom 35%. While the industry has outperformed the broader Zacks Medical sector with an 11% increase over the past year, it has underperformed the S&P 500’s 12% rise. The industry’s forward price-to-earnings ratio stands at 16.75x, lower than the S&P 500’s 20.37x and the Zacks Medical sector’s 22.06x.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
